| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6194066 | Urologic Oncology: Seminars and Original Investigations | 2014 | 5 Pages |
Abstract
ADAM17 was frequently expressed in cRCC. The high expression of ADAM17 was correlated with a worse outcome for patients with cRCC. ADAM17 is a new biomarker for the management of patients with cRCC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Guorong M.D., Ph.D., Fabien M.D., Gang Ph.D., M.D., Anne M.D., Michel M.D., Ph.D., Michèle M.D., Ph.D., Nicolas M.D., Ph.D.,